Section Arrow
PHGE.NYSE-M
- BiomX Inc.
Quotes are at least 15-min delayed:2026/01/06 20:35 EST
Regular Hours
Last
 2.22
-0.04 (-1.77%)
Day High 
2.22 
Prev. Close
2.26 
1-M High
3.9684 
Volume 
49.10K 
Bid
1.94
Ask
2.25
Day Low
2.0662 
Open
2.18 
1-M Low
1.5004 
Market Cap 
3.45M 
Currency 美元 
P/E 0.02 
%Yield -- 
10-SMA 2.05 
20-SMA 2.28 
50-SMA 5.21 
52-W High 22.0571 
52-W Low 0.5338 
Exchange NYSE-M 
Valuation Estimation
EPS (Current/Estimated)
-37.05/-6.01
Enterprise Value
11.90M
Balance Sheet
Book Value Per Share
-5.33
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CYCNCyclerion Therapeutics1.95+0.57+41.30%-- 
ALMSAlumis Inc.16.23+7.92+95.31%0.33PE
MREOMereo BioPharma Group plc0.379-0.1016-21.14%-- 
SLSSELLAS Life Sciences Group4.1-0.9-18.00%-- 
RXRXRecursion Pharmaceuticals4.55+0.18+4.12%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.